DLK Investment Management LLC Has $1.77 Million Stock Holdings in Kenvue Inc. $KVUE

DLK Investment Management LLC trimmed its position in Kenvue Inc. (NYSE:KVUE) by 39.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,727 shares of the company’s stock after selling 67,219 shares during the quarter. DLK Investment Management LLC’s holdings in Kenvue were worth $1,772,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KVUE. Steward Partners Investment Advisory LLC boosted its holdings in shares of Kenvue by 137.9% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 107,733 shares of the company’s stock valued at $2,255,000 after purchasing an additional 62,444 shares in the last quarter. J.W. Cole Advisors Inc. raised its holdings in shares of Kenvue by 3.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock worth $324,000 after buying an additional 574 shares in the last quarter. Inceptionr LLC bought a new stake in shares of Kenvue during the 2nd quarter worth $309,000. Choreo LLC lifted its position in shares of Kenvue by 2.1% during the 2nd quarter. Choreo LLC now owns 38,650 shares of the company’s stock worth $809,000 after buying an additional 800 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in Kenvue by 872.5% in the second quarter. Quadrant Capital Group LLC now owns 33,824 shares of the company’s stock valued at $708,000 after buying an additional 30,346 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE opened at $17.52 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The stock has a market cap of $33.57 billion, a PE ratio of 22.75, a PEG ratio of 3.98 and a beta of 0.51. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The business has a 50-day simple moving average of $18.01 and a two-hundred day simple moving average of $17.13.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.26 earnings per share. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 107.79%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of recent analyst reports. UBS Group lifted their target price on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Argus raised shares of Kenvue to a “hold” rating in a report on Friday, March 6th. Canaccord Genuity Group raised their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Finally, Barclays increased their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, March 6th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.